Overall Goal of the Project

The overall aim of this project is to obtain through multidisciplinary research the information required for better control of the HCV epidemic in Egypt.

Research findings will also support the management of patients infected with HCV genotype 4 around the world, and the development of anti-HCV vaccines.


Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Read more

Scientific Advisory Board Meeting

The Scientific Advisory Board Meeting was held in Paris February 15-16, 2013.

Read more

fp7_01fp7_02 This project is funded
by the European Union